Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Updated

Phase 1/2 trial of TRCN-1023 opens to recruitment

Original source

Phase 1/2 trial of TRCN-1023 in ALS/MND registered (FUNCtion ALS)ClinicalTrials.gov · 29 June 2026 (opens in a new tab)

3 further copies of this report were also considered.

Trial at a glance

Status
Recruiting
Phase
Phase 1/2
Intervention
TRCN-1023 (drug)
Enrolment
30 participants (estimated)
Sites
Germany, the Netherlands
Sponsor
Trace Neuroscience, Inc.
Registration
NCT07674667

Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.

This Phase 1/2 interventional study is recruiting 30 people with ALS, with sites in Germany and the Netherlands. It is testing the drug TRCN-1023, and the registry change is that recruitment has opened.

Why this matters

People with ALS in Germany and the Netherlands may now be able to take part. The registry does not state recruitment status for individual sites.

Trial updates

Recruitment opened — 5 August 2026

  1. 20 July 2026New location
  2. 6 July 2026New location
  3. 29 June 2026Trial registered

Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.

Summarised by Compass 30 August 2026 · updated 30 August 2026 · reported from Germany and the Netherlands

This summary was generated by AI from the reporting behind this development, not from the single article shown first. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?